Atherosclerosis, Cancer and Immune Checkpoint Inhibitors

被引：0

作者：

Canale, Maria Laura ^{[1
]}

Greco, Alessandra ^{[2
]}

Inno, Alessandro ^{[3
]}

Tedeschi, Andrea ^{[4
]}

De Biasio, Marzia ^{[5
]}

Oliva, Stefano ^{[6
]}

Bisceglia, Irma ^{[7
]}

Maurea, Nicola ^{[8
]}

Tarantini, Luigi ^{[9
]}

Gallucci, Giuseppina ^{[10
]}

Gulizia, Michele Massimo ^{[11
]}

Turazza, Fabio Maria ^{[12
]}

Luca, Fabiana ^{[13
]}

Di Fusco, Stefania Angela ^{[14
]}

Riccio, Carmine ^{[15
]}

Navazio, Alessandro ^{[9
]}

De Luca, Leonardo ^{[2
]}

Gabrielli, Domenico ^{[16
,17
]}

Colivicchi, Furio ^{[14
]}

Grimaldi, Massimo ^{[18
]}

Oliva, Fabrizio ^{[19
]}

机构：

[1] Osped Versilia, Azienda USL Toscana Nord Ovest, UOC Cardiol, Lido Di Camaiore, LU, Italy

[2] Fdn IRCCS Policlin San Matteo, Div Cardiol, Pavia, Italy

[3] IRCCS Osped Sacro Cuore Don Calabria, Oncol Med, Negrar Di Valpolicella, VR, Italy

[4] Osped Civile Guglielmo da Saliceto, UOC Cardiol & UT, Piacenza, Italy

[5] Azienda Sanit Univ Friuli Cent, Cardiol, Udine, Italy

[6] IRCCS Ist Tumori Giovanni Paolo II, UOSD Cardiol Interesse Oncol, Bari, Italy

[7] Azienda Osped San Camillo Forlanini, Dipartimento Sci Cardiotoraco Vasc, Serv Cardiol Integrati, Rome, Italy

[8] IRCCS, Fdn G Pascale, SC Cardiol, Naples, Italy

[9] AUSL IRCCS Reggio Emilia, Cardiol Osped, Reggio Emilia, Italy

[10] Polimedica, Melfi, PZ, Italy

[11] Osped Garibaldi Nesima, UOC Cardiol, UOC Cardiol, Catania, Italy

[12] Fdn IRCCS, SC Cardiol, Milan, Italy

[13] Azienda Ospedaliera Bianchi Melacrino Morelli, Cardiol Interventist UTIC, Azienda Osped Bianchi Melacrino Morelli, Reggio Di Calabria, Italy

[14] Presidio Osped San Filippo Neri ASL Roma 1, UOC Cardiol Clin & Riabil, Rome, Italy

[15] AORN St Anna & San Sebastiano, Dipartimento Cardiovasc, Caserta, Italy

[16] Azienda Osped San Camillo Forlanini, UOC Cardiol, Rome, Italy

[17] Fdn Tuo Cuore Heart Care Fdn, Florence, Italy

[18] Osped Gen Regionale F Miulli, UOC Cardiol, Acquaviva Delle Fonti, BA, Italy

[19] ASST Grande Osped Metropolitano Niguarda, Dipartimento Cardiotoracovasc A De Gasperis, Cardiol Emodinam 1, Milan, Italy

来源：

GIORNALE ITALIANO DI CARDIOLOGIA | 2024年 / 25卷 / 10期

关键词：

Atherosclerosis; Cancer; Immune checkpoint inhibitors; Immunotherapy; CARDIOVASCULAR EVENTS; CORONARY CALCIUM; ADVERSE EVENTS; LUNG-CANCER; IMMUNOTHERAPY; INFLAMMATION; MANAGEMENT; BLOCKADE; SEX; CALCIFICATION;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Immunotherapy has revolutionized the treatment of various cancers leading to a clear survival benefit with cured or long-surviving patients. Atherosclerosis and cancer share risk factors and molecular mechanisms and have as their common thread a state of chronic inflammation linked to a deregulation of the immune system. A growing body of evidence is accumulating on the potential worsening effect of immune checkpoint inhibitors on atherosclerosis, with subsequent worsening of patients' long-term cardiovascular risk. The molecular pathways implicated in the growth and deregulation of atherosclerotic plaques seem to be the same (CTLA-4, PD-1, PD-L1) as those on which the anti-tumor effect is exerted. Owing to the increasing number of cancer patients treated with immunotherapy and the improved survival with the possibility of prolonged disease control, it is necessary to know the potential increase in cardiovascular risk for atherosclerosis-related events and to establish all prevention measures to reduce it.

引用

页码：711 / 719

页数：9

共 50 条

[41] The role of immune checkpoint inhibitors in prostate cancer
Surdacki, Gabriel
Szudy-Szczyrek, Aneta
Goracy, Aneta
Chyl-Surdacka, Katarzyna
Hus, Marek
ANNALS OF AGRICULTURAL AND ENVIRONMENTAL MEDICINE, 2019, 26 (01) : 120 - 124
[42] Immune checkpoint inhibitors in lung cancer: an update
Sullivan, Kevin
Preeshagul, Isabel
Budman, Daniel
Seetharamu, Nagashree
FUTURE ONCOLOGY, 2017, 13 (11) : 955 - 959
[43] Unraveling immune checkpoint inhibitors effects on atherosclerosis: mechanisms and preventive approaches
Nardi Agmon, I
Leshem-Lev, D.
Shavit, R.
Gurevitz, C.
Rahat, O.
Gueta, T.
Hochhauser, E.
Eisen, A.
Kornowski, R.
EUROPEAN HEART JOURNAL, 2024, 45
[44] Effects Of Immune-checkpoint Inhibitors On Atherosclerosis In Halted Progression Model
Cilhoroz, Burak T.
Das, Dayasagar
Amadori, Letizia
Eberhardt, Natalia
Smyrnis, Panagiotis
Gourvest, Morgane
Gildea, Michael
Kaur, Ravneet
Moore, Kathryn J.
Giannarelli, Chiara
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2024, 44
[45] CARDIOVASCULAR ONCOLOGY: EXPLORING THE EFFECTS OF IMMUNE CHECKPOINT INHIBITORS ON EXPERIMENTAL ATHEROSCLEROSIS
Poels, K.
den Toom, M.
Reiche, M.
Kusters, P.
Beckers, L.
Seijkens, T.
Lutgens, E.
ATHEROSCLEROSIS, 2019, 287 : E99 - E99
[46] Cancer immune control by immune checkpoint inhibitors requires senescence
Brenner, E.
Schoerg, B. F.
Wieder, T.
Hilke, F.
Schroeder, C.
Kneilling, M.
Pichler, B.
Roecken, M.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (09) : S266 - S266
[47] Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
Hargadon, Kristian M.
Johnson, Coleman E.
Williams, Corey J.
INTERNATIONAL IMMUNOPHARMACOLOGY, 2018, 62 : 29 - 39
[48] Immune Checkpoint Inhibitors
Haanen, John B. A. G.
Robert, Caroline
IMMUNO-ONCOLOGY, 2015, 42 : 55 - 66
[49] Immune checkpoint inhibitors
Hui, Enfu
JOURNAL OF CELL BIOLOGY, 2019, 218 (03): : 740 - 741
[50] Immune checkpoint inhibitors
Kitano, S.
ANNALS OF ONCOLOGY, 2024, 35 : S1305 - S1305

← 1 2 3 4 5 →